Intrinsic value of Stericycle - SRCL

Previous Close

$70.70

  Intrinsic Value

$64.54

stock screener

  Rating & Target

hold

-9%

  Value-price divergence*

-17%

Previous close

$70.70

 
Intrinsic value

$64.54

 
Up/down potential

-9%

 
Rating

hold

 
Value-price divergence*

-17%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of SRCL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  19.29
  2.10
  2.39
  2.65
  2.89
  3.10
  3.29
  3.46
  3.61
  3.75
  3.88
  3.99
  4.09
  4.18
  4.26
  4.34
  4.40
  4.46
  4.52
  4.56
  4.61
  4.65
  4.68
  4.71
  4.74
  4.77
  4.79
  4.81
  4.83
  4.85
  4.86
Revenue, $m
  3,562
  3,637
  3,724
  3,822
  3,933
  4,055
  4,188
  4,333
  4,489
  4,658
  4,838
  5,031
  5,237
  5,456
  5,689
  5,935
  6,197
  6,473
  6,765
  7,074
  7,400
  7,744
  8,107
  8,489
  8,892
  9,316
  9,762
  10,232
  10,726
  11,246
  11,793
Variable operating expenses, $m
 
  3,036
  3,100
  3,173
  3,254
  3,344
  3,442
  3,549
  3,664
  3,788
  3,921
  3,704
  3,855
  4,017
  4,188
  4,369
  4,562
  4,765
  4,981
  5,208
  5,448
  5,701
  5,968
  6,249
  6,546
  6,858
  7,187
  7,532
  7,896
  8,279
  8,682
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,129
  3,036
  3,100
  3,173
  3,254
  3,344
  3,442
  3,549
  3,664
  3,788
  3,921
  3,704
  3,855
  4,017
  4,188
  4,369
  4,562
  4,765
  4,981
  5,208
  5,448
  5,701
  5,968
  6,249
  6,546
  6,858
  7,187
  7,532
  7,896
  8,279
  8,682
Operating income, $m
  434
  600
  623
  649
  678
  711
  746
  784
  825
  870
  917
  1,327
  1,382
  1,439
  1,501
  1,566
  1,635
  1,708
  1,785
  1,866
  1,952
  2,043
  2,139
  2,240
  2,346
  2,458
  2,575
  2,699
  2,830
  2,967
  3,111
EBITDA, $m
  686
  1,065
  1,090
  1,119
  1,151
  1,187
  1,226
  1,268
  1,314
  1,364
  1,416
  1,473
  1,533
  1,597
  1,665
  1,738
  1,814
  1,895
  1,981
  2,071
  2,166
  2,267
  2,373
  2,485
  2,603
  2,727
  2,858
  2,995
  3,140
  3,292
  3,453
Interest expense (income), $m
  89
  102
  105
  108
  112
  116
  121
  127
  133
  139
  146
  153
  161
  169
  178
  188
  198
  208
  219
  231
  244
  257
  271
  286
  301
  317
  335
  353
  372
  392
  413
Earnings before tax, $m
  328
  499
  519
  541
  566
  594
  624
  657
  693
  731
  771
  1,174
  1,221
  1,270
  1,323
  1,378
  1,437
  1,499
  1,565
  1,635
  1,709
  1,786
  1,868
  1,954
  2,045
  2,140
  2,241
  2,347
  2,458
  2,575
  2,698
Tax expense, $m
  120
  135
  140
  146
  153
  160
  169
  177
  187
  197
  208
  317
  330
  343
  357
  372
  388
  405
  423
  441
  461
  482
  504
  528
  552
  578
  605
  634
  664
  695
  729
Net income, $m
  206
  364
  379
  395
  413
  434
  456
  480
  506
  533
  563
  857
  891
  927
  965
  1,006
  1,049
  1,095
  1,143
  1,194
  1,247
  1,304
  1,363
  1,426
  1,493
  1,562
  1,636
  1,713
  1,794
  1,880
  1,970

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  44
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  6,980
  7,075
  7,245
  7,437
  7,651
  7,888
  8,148
  8,429
  8,734
  9,062
  9,413
  9,788
  10,189
  10,615
  11,067
  11,547
  12,055
  12,593
  13,162
  13,763
  14,397
  15,066
  15,772
  16,515
  17,299
  18,124
  18,992
  19,906
  20,868
  21,880
  22,944
Adjusted assets (=assets-cash), $m
  6,936
  7,075
  7,245
  7,437
  7,651
  7,888
  8,148
  8,429
  8,734
  9,062
  9,413
  9,788
  10,189
  10,615
  11,067
  11,547
  12,055
  12,593
  13,162
  13,763
  14,397
  15,066
  15,772
  16,515
  17,299
  18,124
  18,992
  19,906
  20,868
  21,880
  22,944
Revenue / Adjusted assets
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
  0.514
Average production assets, $m
  2,548
  2,600
  2,662
  2,733
  2,812
  2,899
  2,994
  3,098
  3,210
  3,330
  3,459
  3,597
  3,744
  3,901
  4,067
  4,244
  4,431
  4,628
  4,837
  5,058
  5,291
  5,537
  5,796
  6,070
  6,357
  6,661
  6,980
  7,316
  7,669
  8,041
  8,432
Working capital, $m
  231
  265
  272
  279
  287
  296
  306
  316
  328
  340
  353
  367
  382
  398
  415
  433
  452
  473
  494
  516
  540
  565
  592
  620
  649
  680
  713
  747
  783
  821
  861
Total debt, $m
  2,950
  2,986
  3,087
  3,201
  3,329
  3,470
  3,624
  3,791
  3,973
  4,168
  4,377
  4,600
  4,838
  5,092
  5,361
  5,647
  5,949
  6,269
  6,608
  6,965
  7,342
  7,741
  8,160
  8,603
  9,069
  9,560
  10,076
  10,620
  11,192
  11,794
  12,428
Total liabilities, $m
  4,174
  4,210
  4,311
  4,425
  4,553
  4,694
  4,848
  5,015
  5,197
  5,392
  5,601
  5,824
  6,062
  6,316
  6,585
  6,871
  7,173
  7,493
  7,832
  8,189
  8,566
  8,965
  9,384
  9,827
  10,293
  10,784
  11,300
  11,844
  12,416
  13,018
  13,652
Total equity, $m
  2,806
  2,866
  2,934
  3,012
  3,099
  3,195
  3,300
  3,414
  3,537
  3,670
  3,812
  3,964
  4,126
  4,299
  4,482
  4,677
  4,882
  5,100
  5,331
  5,574
  5,831
  6,102
  6,388
  6,689
  7,006
  7,340
  7,692
  8,062
  8,452
  8,861
  9,292
Total liabilities and equity, $m
  6,980
  7,076
  7,245
  7,437
  7,652
  7,889
  8,148
  8,429
  8,734
  9,062
  9,413
  9,788
  10,188
  10,615
  11,067
  11,548
  12,055
  12,593
  13,163
  13,763
  14,397
  15,067
  15,772
  16,516
  17,299
  18,124
  18,992
  19,906
  20,868
  21,879
  22,944
Debt-to-equity ratio
  1.051
  1.040
  1.050
  1.060
  1.070
  1.090
  1.100
  1.110
  1.120
  1.140
  1.150
  1.160
  1.170
  1.180
  1.200
  1.210
  1.220
  1.230
  1.240
  1.250
  1.260
  1.270
  1.280
  1.290
  1.290
  1.300
  1.310
  1.320
  1.320
  1.330
  1.340
Adjusted equity ratio
  0.398
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405
  0.405

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  206
  364
  379
  395
  413
  434
  456
  480
  506
  533
  563
  857
  891
  927
  965
  1,006
  1,049
  1,095
  1,143
  1,194
  1,247
  1,304
  1,363
  1,426
  1,493
  1,562
  1,636
  1,713
  1,794
  1,880
  1,970
Depreciation, amort., depletion, $m
  252
  464
  467
  470
  473
  476
  480
  485
  489
  494
  499
  146
  152
  158
  165
  172
  179
  187
  196
  205
  214
  224
  235
  246
  257
  270
  283
  296
  310
  326
  341
Funds from operations, $m
  577
  828
  846
  865
  886
  910
  936
  964
  995
  1,027
  1,062
  1,003
  1,043
  1,085
  1,130
  1,178
  1,228
  1,282
  1,339
  1,398
  1,461
  1,528
  1,598
  1,672
  1,750
  1,832
  1,918
  2,009
  2,105
  2,205
  2,311
Change in working capital, $m
  30
  5
  6
  7
  8
  9
  10
  11
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  23
  24
  25
  26
  28
  29
  31
  33
  34
  36
  38
  40
Cash from operations, $m
  547
  823
  839
  858
  878
  901
  926
  954
  983
  1,015
  1,049
  989
  1,028
  1,069
  1,113
  1,160
  1,209
  1,262
  1,317
  1,376
  1,438
  1,503
  1,572
  1,644
  1,721
  1,801
  1,886
  1,975
  2,069
  2,167
  2,271
Maintenance CAPEX, $m
  0
  -103
  -105
  -108
  -111
  -114
  -117
  -121
  -125
  -130
  -135
  -140
  -146
  -152
  -158
  -165
  -172
  -179
  -187
  -196
  -205
  -214
  -224
  -235
  -246
  -257
  -270
  -283
  -296
  -310
  -326
New CAPEX, $m
  -136
  -53
  -62
  -71
  -79
  -87
  -95
  -104
  -112
  -120
  -129
  -138
  -147
  -157
  -166
  -176
  -187
  -198
  -209
  -221
  -233
  -246
  -259
  -273
  -288
  -303
  -319
  -336
  -353
  -372
  -391
Cash from investing activities, $m
  -196
  -156
  -167
  -179
  -190
  -201
  -212
  -225
  -237
  -250
  -264
  -278
  -293
  -309
  -324
  -341
  -359
  -377
  -396
  -417
  -438
  -460
  -483
  -508
  -534
  -560
  -589
  -619
  -649
  -682
  -717
Free cash flow, $m
  351
  667
  672
  679
  689
  700
  714
  729
  746
  765
  785
  711
  735
  761
  789
  819
  851
  885
  921
  959
  1,000
  1,043
  1,088
  1,136
  1,187
  1,240
  1,297
  1,356
  1,419
  1,485
  1,555
Issuance/(repayment) of debt, $m
  -281
  80
  101
  114
  128
  141
  154
  168
  181
  195
  209
  223
  238
  253
  269
  286
  303
  320
  338
  357
  377
  398
  420
  442
  466
  491
  517
  544
  572
  602
  633
Issuance/(repurchase) of shares, $m
  -34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -324
  80
  101
  114
  128
  141
  154
  168
  181
  195
  209
  223
  238
  253
  269
  286
  303
  320
  338
  357
  377
  398
  420
  442
  466
  491
  517
  544
  572
  602
  633
Total cash flow (excl. dividends), $m
  28
  747
  772
  794
  817
  841
  868
  897
  927
  960
  994
  934
  973
  1,014
  1,058
  1,104
  1,153
  1,205
  1,259
  1,317
  1,377
  1,441
  1,508
  1,579
  1,653
  1,731
  1,814
  1,900
  1,991
  2,087
  2,188
Retained Cash Flow (-), $m
  -76
  -60
  -68
  -78
  -87
  -96
  -105
  -114
  -123
  -133
  -142
  -152
  -162
  -173
  -183
  -194
  -206
  -218
  -230
  -243
  -257
  -271
  -286
  -301
  -317
  -334
  -352
  -370
  -390
  -410
  -431
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  687
  704
  716
  730
  745
  763
  782
  804
  827
  852
  782
  811
  842
  875
  910
  947
  987
  1,029
  1,073
  1,120
  1,170
  1,222
  1,278
  1,336
  1,397
  1,462
  1,530
  1,602
  1,677
  1,757
Discount rate, %
 
  8.20
  8.61
  9.04
  9.49
  9.97
  10.47
  10.99
  11.54
  12.12
  12.72
  13.36
  14.02
  14.73
  15.46
  16.24
  17.05
  17.90
  18.79
  19.73
  20.72
  21.76
  22.84
  23.99
  25.19
  26.45
  27.77
  29.16
  30.61
  32.15
  33.75
PV of cash for distribution, $m
 
  635
  597
  552
  508
  463
  420
  377
  336
  295
  257
  197
  168
  141
  117
  95
  76
  60
  46
  35
  26
  19
  13
  9
  6
  4
  3
  2
  1
  1
  0
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States and internationally. The company collects and processes regulated and specialized waste for disposal services, as well as collects personal and confidential information for secure destruction. It offers regulated solutions for medical waste disposal, pharmaceutical waste disposal, and hazardous waste management; sustainability solutions for expired or unused inventory; and secures information destruction of documents and e-media. The company’s compliance solutions comprise Steri-Safe and clinical services programs for training and consulting; inbound/outbound communications; data reporting; and other regulatory compliance services. It also provides reusable sharps disposal management services, integrated waste stream solutions program, and regulated recall and returns management services for expired or recalled products. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, and long-term care facilities; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Lake Forest, Illinois.

FINANCIAL RATIOS  of  Stericycle (SRCL)

Valuation Ratios
P/E Ratio 29.2
Price to Sales 1.7
Price to Book 2.1
Price to Tangible Book
Price to Cash Flow 11
Price to Free Cash Flow 14.6
Growth Rates
Sales Growth Rate 19.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 18.3%
Cap. Spend. - 3 Yr. Gr. Rate 13.3%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity 102.5%
Total Debt to Equity 105.1%
Interest Coverage 5
Management Effectiveness
Return On Assets 3.7%
Ret/ On Assets - 3 Yr. Avg. 6%
Return On Total Capital 3.5%
Ret/ On T. Cap. - 3 Yr. Avg. 6.3%
Return On Equity 7.4%
Return On Equity - 3 Yr. Avg. 12.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 42.2%
Gross Margin - 3 Yr. Avg. 42.5%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 21.5%
Operating Margin 12.2%
Oper. Margin - 3 Yr. Avg. 16.8%
Pre-Tax Margin 9.2%
Pre-Tax Margin - 3 Yr. Avg. 14%
Net Profit Margin 5.8%
Net Profit Margin - 3 Yr. Avg. 9.2%
Effective Tax Rate 36.6%
Eff/ Tax Rate - 3 Yr. Avg. 34.7%
Payout Ratio 18.9%

SRCL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRCL stock intrinsic value calculation we used $3562 million for the last fiscal year's total revenue generated by Stericycle. The default revenue input number comes from 2016 income statement of Stericycle. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRCL stock valuation model: a) initial revenue growth rate of 2.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.2%, whose default value for SRCL is calculated based on our internal credit rating of Stericycle, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Stericycle.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRCL stock the variable cost ratio is equal to 83.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SRCL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Stericycle.

Corporate tax rate of 27% is the nominal tax rate for Stericycle. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRCL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRCL are equal to 71.5%.

Life of production assets of 24.7 years is the average useful life of capital assets used in Stericycle operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRCL is equal to 7.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2806 million for Stericycle - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 84.584 million for Stericycle is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Stericycle at the current share price and the inputted number of shares is $6.0 billion.

RELATED COMPANIES Price Int.Val. Rating
SMED Sharps Complia 5.26 0.38  str.sell
WM Waste Manageme 75.25 35.06  str.sell
CLH Clean Harbors 50.25 24.05  str.sell
ECOL US Ecology 46.20 18.70  str.sell

COMPANY NEWS

▶ [$$] Firm Discloses SEC Subpoena in Bribery Probe   [10:39AM  The Wall Street Journal]
▶ Stericycle subpoenaed in federal anti-corruption probes   [Aug-09-17 06:14PM  MarketWatch]
▶ Stericycle Was the S&P 500s Top Gainer on August 3   [Aug-07-17 09:11AM  Market Realist]
▶ Organic Growth Pushes Stericycle Inc's Revenue Higher   [Aug-04-17 12:08PM  Motley Fool]
▶ ETFs with exposure to Stericycle, Inc. : August 4, 2017   [Aug-03-17 09:28PM  Capital Cube]
▶ The Hot Stock: Stericycle Jumps 8.9%   [06:09PM  Barrons.com]
▶ Stericycle Inc: Buy the Dip?   [Jul-20-17 07:34PM  Motley Fool]
▶ ETFs with exposure to Stericycle, Inc. : July 7, 2017   [Jul-07-17 03:31PM  Capital Cube]
▶ ETFs with exposure to Stericycle, Inc. : June 26, 2017   [Jun-26-17 04:57PM  Capital Cube]
▶ ETFs with exposure to Stericycle, Inc. : June 15, 2017   [Jun-15-17 03:22PM  Capital Cube]
▶ Stericycle to Present at Investor Conference in June   [May-23-17 05:30PM  GlobeNewswire]
▶ Stericycle tops Street 1Q forecasts   [May-04-17 04:12PM  Associated Press]
▶ ETFs with exposure to Stericycle, Inc. : April 17, 2017   [Apr-17-17 01:07PM  Capital Cube]
▶ Stericycle Setting Up for a Breakout   [Apr-13-17 03:17PM  TheStreet.com]
▶ Stericycle to Participate in Two Investor Events in May   [Apr-12-17 04:02PM  GlobeNewswire]
▶ ETFs with exposure to Stericycle, Inc. : April 5, 2017   [Apr-05-17 05:30PM  Capital Cube]
▶ 3 Profitable Healthcare Services Firms at Good Prices   [Mar-10-17 06:00AM  Morningstar]
▶ Goldman Sachs Relents: Stericycle Upgraded to Neutral   [Mar-07-17 12:33PM  Motley Fool]
▶ Stericycle Statement on Class Certification   [02:23PM  GlobeNewswire]
▶ The Hot Stock: Stericycle Jumps 7.7%   [Feb-16-17 04:36PM  at Barrons.com]
▶ Why Stericycle Stock Jumped 12% on Thursday   [01:05PM  at Motley Fool]
▶ 3 Stocks the Smartest Investors are Buying Right Now   [Dec-20-16 07:36AM  at Motley Fool]
▶ 10 Biggest Stock Market Flops of 2016   [Dec-16-16 10:10AM  at Kiplinger]
Stock chart of SRCL Financial statements of SRCL
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.